Promising results from an early stage, multicenter clinical trial led by researchers at Temple University School of Medicine have shown that a novel drug that alters the behavior of cancer cells may help patients with leukemia, as well as those with potentially dangerous blood disorders that frequently lead to leukemia. The findings, while preliminary, could lead to a new approach to treat various forms of cancer using a type of drug called a methylation inhibitor that seeks to modify changes to DNA that lead to cancer.